3. Treatment of ACS Part 2 (Working Diagnosis of STEMI vs NSTE ACS, Arabic Version)

Sdílet
Vložit
  • čas přidán 4. 07. 2024
  • In this video, the specific recommedations regarding the indications for revascularization and for pharmacotherapy are compared in the working diagnosis of STEMI vs. NSTE-ACS.
    0:00 Reperfusion Indications in STEMI
    9:17 Pharmacotherapy in STEMI
    12:49 Fibrinolytic Therapy for STEMI
    19:53 Reperfusion Indications in NSTE-ACS
    22:53 Pharmacotherapy in NSTE-ACS
    2023 ESC Guidelines for the Management of Acute Coronary Syndromes
    www.escardio.org/Guidelines/C...
    2023 ESC Guidelines for the management of acute coronary syndromes Supplementary data
    oup.silverchair-cdn.com/oup/b...
    Percutaneous Myocardial Revascularization in Late-Presenting Patients With STEMI
    pubmed.ncbi.nlm.nih.gov/34556...
    Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms.
    jamanetwork.com/journals/jama...
    Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial
    www.ncbi.nlm.nih.gov/pmc/arti...
    ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up
    pubmed.ncbi.nlm.nih.gov/25161...
    Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. STREAM trial
    www.nejm.org/doi/full/10.1056...
    Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme
    pubmed.ncbi.nlm.nih.gov/31539...
    ISAR-REACT 5 trial. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
    pubmed.ncbi.nlm.nih.gov/31475...
    Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
    pubmed.ncbi.nlm.nih.gov/11530...
    GRACE ACS Risk and Mortality Calculator
    www.mdcalc.com/calc/1099/grac...

Komentáře • 1